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Introduction: To determine the prevalence of chronic kidney disease and nephrolithiasis in people with gout, and
the association between gout and prevalent or incident chronic kidney disease and nephrolithiasis.
Methods: Systematic review and meta-analysis of epidemiological studies. Data sources; MEDLINE, EMBASE and
CINAHL databases, hand-searched reference lists, citation history and contact with authors. Eligibility criteria: cohort,
case–control or cross-sectional studies which examined the occurrence of chronic kidney disease or nephrolithiasis
amongst adults with gout (with or without a non-gout comparator group) in primary care or general population
samples. Prevalence and risk estimate meta-analyses were performed using a random-effects model.
Results: Seventeen studies were included in the meta-analysis (chronic kidney disease n = 7, nephrolithiasis n = 8,
both n = 2). Pooled prevalence estimates of chronic kidney disease stage ≥3 and self-reported lifetime nephrolithiasis in
people with gout were 24% (95% confidence interval 19% to 28%) and 14% (95% CI 12% to 17%) respectively. Gout
was associated with both chronic kidney disease (pooled adjusted odds ratio 2.41, 95% confidence interval 1.86 to
3.11) and self-reported lifetime nephrolithiasis (1.77, 1.43 to 2.19).
Conclusions: Chronic kidney disease and nephrolithiasis are commonly found amongst patients with gout. Gout
is independently associated with both chronic kidney disease and nephrolithiasis. Patients with gout should be
actively screened for chronic kidney disease and its consequences.Introduction
Gout is the most prevalent inflammatory arthritis, affecting
2.4% of adults in the UK [1]. Gout is associated with
considerable co-morbidity including hypertension, diabetes
mellitus, obesity, metabolic syndrome, and vascular disease
[2]. Associations between gout and renal disease and
nephrolithiasis have long been recognised, yet early studies
undertaken in specialist secondary care populations are
likely to be unrepresentative of most patients with gout
who are managed exclusively in primary care settings [3-6].
To the best of our knowledge, no previous systematic re-
views examining this association have been performed.
Chronic kidney disease (CKD) stages 3 to 5 (glomeru-
lar filtration rate <60 ml/minute/1.73 m2) affects 8.5% of
the UK population, is more common in females than* Correspondence: e.roddy@keele.ac.uk
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stated.males (10.6% vs. 5.8%), and is associated with both all-
cause mortality and cardiovascular disease [7,8]. If left
untreated, CKD may progress to end-stage renal disease
(ESRD) requiring expensive renal replacement therapy
(RRT) [9]. CKD is an independent risk factor for the devel-
opment of gout [10,11] yet there are several reasons to ex-
plain why gout may predispose to renal disease, including
hyperuricaemia, chronic inflammation, co-morbid hyper-
tension and diabetes mellitus, and use of nonsteroidal anti-
inflammatory drugs. The management of gout in patients
with renal disease is challenging because nonsteroidal anti-
inflammatory drugs and colchicine should be used with
caution and lower doses of allopurinol are required [12].
The lifetime prevalence of nephrolithiasis is approxi-
mately 8.8% [13]. Kidney stones most commonly present
as renal colic but can be complicated by infection, renal
tract obstruction requiring surgical intervention, and
renal failure [14]. Gout is associated with lower urinary
pH theoretically predisposing to the formation of bothral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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obesity, and hypertension are also known to be inde-
pendent risk factors for nephrolithiasis [16-18].
The objectives of this systematic review and meta-
analysis of epidemiological studies were to quantify the
prevalence of CKD and nephrolithiasis in gout, and to de-
termine whether gout is associated with prevalent or inci-
dent CKD and nephrolithiasis in the general population.
Methods
Data sources and searches
A systematic literature search was undertaken by two co-
investigators (MJR and ER) in the MEDLINE, EMBASE,
and CINAHL databases using the National Health
Service’s Healthcare Databases Advanced Search from
inception date to November 2013 for epidemiological
studies examining the association between gout and ei-
ther CKD or nephrolithiasis. Search terms pertaining to
gout were combined with terms describing the outcome
(CKD or nephrolithiasis) and observational study design
using the Boolean operator “AND”. No unpublished
data sources were searched. The references and citation
history of all relevant studies were checked for add-
itional data sources.
Eligibility criteria
Eligible studies were required to include adults with gout
(with or without a nongout comparator group), describe
the occurrence of CKD or nephrolithiasis amongst adults
with gout (and nongout comparator group where in-
cluded), be of an epidemiological design (cross-sectional,
cohort, case–control), and have been undertaken in a pri-
mary care or general population sample. No geographical
or language restrictions were imposed. Conference ab-
stracts were not included.
Study selection
MJR and ER independently screened the title and ab-
stract of all identified studies. Studies which could not
be excluded on title/abstract review were retained for
full-text review undertaken by the same reviewers. At
both the title/abstract and full-text review stages, dis-
agreement over study eligibility was resolved by consen-
sus discussion between the reviewers. A third reviewer
(CDM) was available where disagreement could not be
resolved by consensus.
Data extraction and quality assessment
The following data were extracted independently by the
same two reviewers from studies meeting the inclusion
criteria: date and location of study, study population and
size, study type, demographic characteristics (age and gen-
der), method of ascertainment of gout and CKD/nephro-
lithiasis, prevalence and incidence of CKD/nephrolithiasisin gout and comparator populations, unadjusted and ad-
justed risk estimates (odds ratio, relative risk, hazards
ratio) and corresponding 95% confidence interval (CI) or
standard error, and details of covariates included in multi-
variate models. Studies utilising any method of gout ascer-
tainment (for example, crystal identification, classification
criteria, clinical diagnosis) were included. Staging of CKD
was defined according to the National Kidney Foundation
classification (stage 1, glomerular filtration rate ≥90 ml/
minute/1.73 m2; stage 2, glomerular filtration rate 60 to
89 ml/minute/1.73 m2; stage 3, glomerular filtration rate
30 to 59 ml/minute/1.73 m2; stage 4, glomerular filtra-
tion rate 15 to 29 ml/minute/1.73 m2; stage 5 (ESRD),
glomerular filtration rate <15 ml/minute/1.73 m2) [19].
Assessment of methodological quality was performed
independently by the same two reviewers using the
Newcastle–Ottawa quality appraisal tool with additional
items regarding the method of diagnosis of gout, CKD,
and nephrolithiasis [20]. Disagreement over data extrac-
tion and assessment of methodological quality was re-
solved by consensus discussion between the reviewers.
Authors were contacted to request additional informa-
tion and data where necessary.
Data analysis
Estimates of point/lifetime prevalence of CKD/nephro-
lithiasis in adults with gout and, where possible, risk
estimates of the association between gout and CKD/
nephrolithiasis were calculated. These estimates were
derived from summary 2 × 2 tables, together with re-
gression estimates arising from adjusted analyses using
logistic and Cox regression.
To normalize the distribution, prevalence rates were
transformed by means of the logit event rate:
Lp ¼ Ln p = 1 ‐ pð Þð Þ
with p being the prevalence rate, Ln the natural logarithm,
and Lp the logit event rate. The sampling variance of each
logit event rate, V(Lp), was calculated by means of:
V Lpð Þ ¼ 1 = npð Þ þ 1 = n 1 ‐ pð Þð Þ
with n being the sample size. Once the statistical ana-
lyses were carried out, the results were back transformed
to prevalence rates to facilitate their interpretation.
Separate analyses were undertaken for CKD and nephro-
lithiasis. Where sufficient data were present in individual
studies but risk estimates were not reported, these were
calculated using the available data. Pooled estimates were
calculated using a random effects model. The 95% CIs and
forest plots were produced for all pooled estimates.
Heterogeneity was assessed visually with forest plots, and
quantified numerically using the I2 index [21] and Cochran’s
Q test. The I2 test describes the percentage of variation
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Meta-analyses were performed using the metan command
within STATA 12.1 (StataCorp, College Station, TX, USA).
Results
Study selection
The search identified 2,032 potentially relevant articles:
after removal of duplicates, 1,419 remained (Figure 1).
Following title/abstract review, 1,333 articles were ex-
cluded. Of the 86 articles remaining, 57 were excluded
after full-text review and 29 met the eligibility criteria.
Seventeen studies contained data suitable for pooling.
Reasons for exclusion are shown in Figure 1.
Study characteristics
Twelve studies examined CKD [22-33], 15 studies ex-
amined nephrolithiasis [13,34-47], and two studies ex-
amined both CKD and nephrolithiasis [48,49] (Table 1).
Nineteen cross-sectional studies [13,22,25,27,29,30,32,
34-38,40-42,46-49], one case–control study [26], and
nine cohort studies [23,24,28,31,33,39,43-45] were iden-
tified. Six of the nine cohort studies included relevant
outcome data only at baseline and so were treated as
cross-sectional studies [24,31,33,43-45].
Fourteen studies were performed in the USA [13,23,
25-27,32,34,38,39,41,43-45,48], four in the UK [36,37,40,
49], five in Taiwan [24,28,30,31,33], and one study each in
China [22], Denmark [35], France [29], Indonesia [42],
Italy [46], and Japan [47]. One study restricted participa-
tion to people aged over 65 years [44] and three studies
included only males [35,39,47]. Fourteen studies wereFigure 1 Selection of studies included in the review. CKD, chronic kidney dundertaken in large healthcare databases [23-28,31,33,
40,41,43-46] whereas 15 studies used empirically collected
data [13,22,29,30,32,34-39,42,47-49].
Assessment of methodological quality
Only three of 29 studies based the diagnosis of gout on
validated clinical classification criteria: two studies [39,42]
used the American Rheumatism Association criteria [50],
and one study [34] used the New York and Rome criteria
[51,52]. No studies based the diagnosis of gout on crystal
identification. Three studies reported combined outcomes
for gout and hyperuricaemia [26,30,47]. Nine studies used
biochemical measures to define CKD [22,24,25,27,29,
30,32,48,49], four studies examined ESRD requiring RRT
[23,26,28,31], whereas nine of 17 studies of nephrolithiasis
defined outcome by self-report [13,34,35,38,39,42,47-49],
six studies used medical record linkage [40,41,43-46],
and two studies used a general practitioner completed
questionnaire [36,37].
Participants were considered not representative of the
typical community gout patient in eight studies due to
including only patients prescribed urate-lowering ther-
apy [25,44,45], only males [35,39,47], or only people with
chronic gout [42] and one study being undertaken in a
Veterans database which resulted in a predominantly male
(99%) older population (mean age 72 years) [27]. All stud-
ies featuring a nongout comparator group had drawn this
from the same community as the exposed cohort. Re-
sponse and data usage rates were frequently not reported
[13,26,38,41-45,48], Two surveys reported response rates
under 60% [30,49] and two database studies based in aisease.
Table 1 Characteristics of included studies
First author Study period Location Source of data/
study population
Study type Total sample Mean age (SD)a % male Gout ascertainment Outcomes reported (method
of ascertainment)
Chen [22] 2006 China Residents of
Changning district of
Shanghai
CS 2,554 58.4 (SE 15.3) 36 Self-report Adjusted ORs for CKD any stage
and CKD stage ≥3 (biochemical
measurement)
Hsu [23] 1964 to 2000 USA Kaiser Permanente
Northern California
linked to US Renal
Data System
Cohort 177,570 ESRD 42.3 (10.3) ESRD 59 Self-reported
physician diagnosis
Univariate and multivariate HRs
for ESRD requiring RRT (record
linkage)No ESRD 40.7 (14.0) No ESRD 46
Kuo [24] 2000 to 2006 Taiwan Chang Gung
Memorial Hospital
health screening
programme
CS data from
cohortb
61,527 Males 49.1 (11.0) 56 Self-reported or ICD
code or crystal
identification
Prevalence of CKD stage ≥3
(biochemical measurement)
Females 50.8 (10.8)
Fuldeore [25] 2002 to 2005 USA Managed Healthcare
Database
CS 3,929 CKD CKD ICD code on two
occasions or ICD code
plus gout medication
Prevalence of CKD stage 2, 3 and
4 (biochemical measurement)
54.3 (NR) 86
No CKD No CKD
47.8 (9.0) 89
Johnson [26] 1997 to 2004 USA Kaiser Permanente
North West
CC 5,335 64.4 (NR) 46 ICD code or SUA
≥7 mg/dl
Unadjusted and adjusted ORs for
ESRD requiring RRT (medical
record review)
Keenan [27] 2007 to 2008 USA New York Veterans
Affairs database
CS 575 71.8 (11.6) 99 ICD code Prevalence of CKD stage ≥3
(biochemical measurement or
ICD code)
Yu [28] 2000 to 2008 Taiwan Taiwan National
Health Insurance
Database
Cohort 656,108 41.1 (15.6) 73 ICD code on two
occasions or ICD code
plus gout medication
Multivariate HR for ESRD
requiring RRT (record linkage)
O’Sullivan [34] 1964 USA Population of
Sudbury,
Massachusetts
CS 4,626 NR NR New York/Rome
criteria
Prevalence of nephrolithiasis
(self-report, not defined)
Schaffalitzky De
Muckadell [35]
1973 Denmark Male office workers
aged 40 to 59 years in
Copenhagen
CS 312 NR 100 Self-reported
physician diagnosis
Prevalence of nephrolithiasis
(self-report, not defined)
Currie [36] 1969 to 1975 UK General practice
records
CS 604 52.3 (NR) 77 GP diagnosis Prevalence of nephrolithiasis (GP
diagnosis)
Currie [37] 1976 UK General practice
records
CS 64,454 NR NR GP diagnosis Incidence of nephrolithiasis (GP
diagnosis)
Kramer [38] 1988 to 1994 USA National Health and
Nutrition Examination
Survey (NHANES) III
CS 17,030 Stones 53.7 (0.7) 48 Self-reported
physician diagnosis
Prevalence and adjusted ORs for
nephrolithiasis (self-reported
lifetime prevalence)No stones 44.2 (0.4)
Kramer [39] 1986 to 1998 USA Health Professionals
Follow-up Study
Cohort 51,529 Gout 59.9 (9.1) 100 Self-reported
physician diagnosis,
ARA criteria
Prevalence and adjusted RRs for
nephrolithiasis (self-reported
lifetime prevalence)No gout 54.4 (9.8)
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Mikuls [40] 1990 to 1999 UK General Practice
Research Database
(GPRD)
CS 207,350 Gout 60.5 (15.4) 46 GP d nosis Prevalence, unadjusted and
adjusted ORs for nephrolithiasis
(medical records)OA controls 66.8 (13.4)
Harrold [41] 1999 to 2003 USA Health Maintenance
Organisations (HMO)
Research Network
Centre for Education
and Research on
Therapeutics (CERT)
CS 6,133 Males 58 (14) 81 ICD c e on two
occa s
Prevalence of nephrolithiasis
(ICD code)
Females 70 (12)
Padang [42] Not stated Indonesia Community Health
Centres in Northern
Sulawesi
CS 380 NR NR ≥3 a ks of gout/
year /or tophi plus
ARA eria
Prevalence of nephrolithiasis
(self-report, not defined)
Sarawate [43] 1999 to 2004 USA Managed Care
Database
CS data from
cohortb
5,942 57.4 (14.1) 76 ICD c e on two
occa s or ICD code
plus t medication
Prevalence of nephrolithiasis
(ICD code)
Solomon [44] Not stated USA US Medicare system
and Pharmacy
Assistance Contract
for the Elderly (PACE)
CS data from
cohortb
9,823 Male 78 (7) 16 Use o LT Prevalence of nephrolithiasis
(medical records)
Female 80 (7)
Harrold [45] 2000 to 2006 USA Health Maintenance
Organisations (HMO)
Research Network
Centre for Education
and Research on
Therapeutics (CERT)
CS data from
cohortb
4,166 62 (14) 75 ICD c e plus use of
ULT
Prevalence of nephrolithiasis
(ICD code)
Roddy [49] 2005 UK Registered population
of two general
practices in
Nottingham
CS 3,082 Gout 63.8 (10.6) Gout 81 Self-r rted gout,
valid d by
rheum tologist
Prevalence of CKD stage ≥3, ≥4
(biochemical measurement) and
nephrolithiasis (self-reported
lifetime prevalence)
No gout 57.0 (14.4) No gout 41
Zhu [48] 2007 to 2008 USA National Health and
Nutrition Examination
Survey (NHANES)
CS 5,707 47 (NR) 48 Self-r rted
phys n diagnosis
Prevalence and adjusted OR for
CKD stage ≥2, ≥3c (biochemical
measurement) and
nephrolithiasis (self-reported
lifetime prevalence)
Liote [29] 2008 to 2009 France General Practitioner
data from GOSPEL
survey
CS 810 62.7 (11.3) 87.2 Phys n diagnosis Prevalence of CKD stage ≥3, ≥4
(biochemical measurement)
Lin [30] 2007 Taiwan Community-based
survey, sampling via
Household Register
Database
CS 3,352 47.5 (17.4) 48.6 Self-r rted
phys n diagnosis of
gout
hype icaemia
Prevalence of CKD stage ≥3
(biochemical measurement)
Kuo [31] 2000 to 2008 Taiwan Longitudinal Health
Insurance Database
CS data from
cohortb
704,503 42.73 (16.6) Gout 70.3,
no gout 50.4
ICD c e Prevalence and unadjusted OR
for ESRD requiring RRT (record
linkage)
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Table 1 Characteristics of included studies (Continued)
Krishnan [32] 2009 to 2010 USA National Health and
Nutrition Examination
Survey
CS 5,589 44 (21) 49 Self-reported
physician diagnosis
Prevalence of CKD stage 2, 3,
≥4 (biochemical measurement)
Kok [33] 2003 to 2007 Taiwan Taiwan National
Health Insurance
Database
CS data from
cohortb
3,858,840 NR 48.3 ICD code on three
occasions
Prevalence of CKD, stages not
specified (ICD code)
Trifiro [46] 2005 to 2009 Italy Health Search/
Cegedim Strategic
Data Longitudinal
Patient Database
CS 12,276 NR 74 ICD code, related
keywords for free text
search
Prevalence and unadjusted OR
for nephrolithiasis (medical
records)
Scales [13] 2007 to 2010 USA National Health and
Nutrition Examination
Survey
CS 12,110 NR NR NR Adjusted OR for nephrolithiasis
(self-reported lifetime prevalence)
Ando [47] 1995 to 2001 Japan Men undergoing
medical examination
at Gifu Prefectural
Center for Health
Check and Health
Promotion
CS 13,418 Controls 48.5 (8.8),
past stones 49.7 (8.4)
100 Receiving medical
treatment for gout or
SUA ≥7.0 mg/dl
Prevalence nephrolithiasis
(self-reported lifetime prevalence)
ARA, American Rheumatism Association; CC, case–control study; CKD, chronic kidney disease; CS, cross-sectional; ESRD, end-stage renal disease; GP, general practitioner; HR, hazard ratio; ICD, International Classification
of Disease; NR, not reported; OA, osteoarthritis; OR, odds ratio; RR, relative risk; RRT, renal replacement therapy; SD, standard deviation; SE, standard error; SUA, serum uric acid level; ULT, urate-lowering therapy.
aAssumed to be SD unless otherwise stated. bCohort study reporting only cross-sectional data relevant to this review. cCKD stages clarified with authors; CSD, Cegedim Strategic Data.
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able to them [24,31].
Of the three cohort studies, none reported rates of at-
trition and one did not state whether the outcome
(ESRD) was absent at the start of the study [23]. Length
of follow-up was deemed adequate to determine out-
come in all three studies.
Selection for meta-analysis
Seventeen out of 29 studies were included in the meta-
analysis [13,22-24,28-30,32,34,35,38,39,42,46-49]. Two
studies examining CKD were deemed unsuitable for
pooling due to use of diagnostic codes [27,33] rather
than biochemical testing to ascertain CKD that has been
shown to significantly underestimate prevalence [53,54].
One study demonstrated significant incompleteness of
biochemical data and was not pooled [25]. Ten out of 17
studies examining self-reported nephrolithiasis were
pooled [13,34,35,38,39,42,46-49], and six studies were
deemed too methodologically different to pool due to
using a general practitioner completed questionnaire
[36] or diagnostic codes and/or a limited time period for
ascertaining nephrolithiasis [40,41,43-45]. Three studies
reported outcomes that were not reported by other stud-
ies, thus precluding meta-analysis [26,31,37].
Prevalence and risk of chronic kidney disease in gout
Six studies provided suitable data to allow the pooled
prevalence of CKD stage ≥3 in people with gout to beFigure 2 Forest plot of individual and pooled (random effects) prevalencecalculated [24,29,30,32,48,49]. Further data [29,30] and
outcome clarification [48] was requested from the au-
thors of three of these studies, enabling their inclusion.
No reply was received from the authors of a further
paper from whom the prevalence of CKD in those with
and without gout was requested. The pooled prevalence
estimate of CKD stage ≥3 in people with gout was 24%
(95% CI 19%, 28%) (Figure 2). Statistically significant het-
erogeneity was identified (I2 = 84.3%, P <0.001). Data from
three studies [29,32,49] were pooled providing a preva-
lence estimate of CKD stage ≥4 in gout of 2% (95% CI 0%,
4%) (I2 = 82.5%, P = 0.003).
Comparing patients with gout to those without gout,
the pooled unadjusted odds ratio (OR) between gout
and CKD stage ≥3 was 4.32 (95% CI 3.82, 4.89) (Figure 3)
based on the findings of three studies [24,30,48]. Pooling
an age-adjusted and gender-adjusted OR and two multi-
variate ORs (adjustment included age, gender, obesity,
hypertension, and diabetes mellitus) between gout and
CKD stage ≥3 resulted in an adjusted OR of 2.41 (95% CI
1.86, 3.11) (Figure 3) [22,30,48]. There was no significant
heterogeneity identified for either pooled unadjusted or
adjusted ORs (unadjusted I2 = 0.0%, P = 0.803; adjusted
I2 = 0.0%, P = 0.416).
One study reported prevalence of ESRD requiring RRT
in gout (0.6%) and provided an unadjusted OR for ESRD
in gout versus no gout (OR 2.65; 95% CI 2.25, 3.12) [31].
One retrospective matched case–control study compared
the likelihood of a prior combined exposure of gout ors of chronic kidney disease stage ≥3 in gout. CI, confidence interval.
Figure 3 Forest plot of individual and pooled (random effects) unadjusted and adjusted odds ratios between gout and chronic kidney disease
stage ≥3. CI, confidence interval.
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and controls without ESRD matched for age, gender, and
year of RRT (adjusted OR 2.51; 95% CI 1.78, 3.54) [26].
Following contact with the authors of one study to
provide an unadjusted hazard ratio (HR) (95% CI) be-
tween gout and ESRD [28], there were two prospective
cohort studies [23,28] that provided suitable data to
allow a pooled unadjusted HR between gout and inci-
dent ESRD to be calculated (HR 2.69; 95% CI 1.00, 4.39).
Mean follow-up periods were 24.5 years in one study
[23] and 8.0 years overall in the other [28]. Significant
heterogeneity was identified (I2 93.1%, P <0.001). We con-
tacted the authors of one of these studies to request an ad-
justed HR (95% CI) between gout and incident ESRD [23].
The authors replied but were unable to provide this infor-
mation. Only one study provided a multivariate adjusted
HR between gout and incident ESRD (HR 1.57; 95% CI
1.38 to 1.79; adjusted for age, sex, diabetes and hyper-
tension) [28].
Prevalence and risk of nephrolithiasis in gout
We were able to use additional unpublished data from
one of our previous studies [49] concerning the prevalence
of self-reported lifetime nephrolithiasis in people with gout
and ORs (95% CI) between gout and self-reported lifetime
nephrolithiasis, unadjusted and then adjusted, firstly, for
age and gender and, secondly, for age, gender, diabetes,hypertension, and diuretic use. The pooled estimate of the
prevalence of nephrolithiasis in people with gout was 14%
(95% CI 12%, 17%) (Figure 4) based on the findings of eight
studies [34,35,38,39,42,47-49]. Significant statistical hetero-
geneity was identified (I2 = 79.4%, P <0.001).
Eight studies [34,35,38,39,42,46,48,49] provided suit-
able data to calculate a pooled unadjusted OR between
gout and self-reported prevalence of nephrolithiasis (OR
2.66; 95% CI 2.16, 3.27) (Figure 5). The pooled age-
adjusted and gender-adjusted OR was 1.87 (95% CI 1.25,
2.80), based on the findings of four studies [42,47-49].
Three studies provided suitable data to permit a pooled
multivariate adjusted OR to be calculated (OR 1.77; 95%
CI 1.43, 2.19) [13,38,49]. All three studies adjusted for age,
gender, and body mass index; two studies additionally ad-
justed for hypertension [38,49] and the other study for
diabetes mellitus [13]. Significant heterogeneity was iden-
tified for the pooled unadjusted and the age-adjusted and
gender-adjusted ORs (unadjusted I2 = 69.1%, P = 0.002;
age-adjusted and gender-adjusted I2 = 70.2%, P = 0.018)
but not for the multivariate pooled estimate (I2 = 0.0%,
P = 0.510). One prospective study found men with gout
to have a relative risk of 2.12 (95% CI 1.22, 3.68) of de-
veloping incident nephrolithiasis over a 12-year period
compared with men without gout, after adjustment for
age, body mass index, diuretic use, hypertension, and
dietary factors [39].
Figure 5 Forest plot of individual and pooled (random effects) unadjusted and adjusted odds ratios between gout and nephrolithiasis.
CI, confidence interval.
Figure 4 Forest plot of individual and pooled (random effects) prevalences of nephrolithiasis in gout. CI, confidence interval.
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When pooling the six studies describing the prevalences
of CKD stage ≥3, Egger’s test yielded a borderline result
of P = 0.05. No evidence of small study effects was seen
for nephrolithiasis (Egger’s test P = 0.548).
Discussion
In this systematic review and meta-analysis of population-
based epidemiological studies, renal disease and nephro-
lithiasis were common findings in people with gout. The
pooled prevalence estimates of CKD stage ≥3 and self-
reported nephrolithiasis in people with gout were 24% and
14% respectively. Furthermore, after adjustment for con-
founding variables, people with gout were more than
twice as likely to have CKD stage ≥3 (OR 2.41) and over
one and a half times (OR 1.77) as likely to have ever had
nephrolithiasis as people who did not have gout. Most
studies employed a cross-sectional design and there was a
paucity of prospective studies. The pooled unadjusted HR
for incident ESRD in people with gout was 2.69; however,
the lower limit of the 95% CI bordered unity. Only one
study provided an adjusted HR which suggested that gout
is an independent risk factor for incident ESRD (HR 1.57).
Similarly, the single prospective study of the risk of de-
veloping nephrolithiasis found people with gout to have
twice the risk (adjusted relative risk 2.12) of people
without gout.
To our knowledge, this is the first meta-analysis of associ-
ations between gout and CKD/nephrolithiasis. Strengths of
our methodology include the comprehensive search strat-
egy and literature review process undertaken by two
independent reviewers, translation of non-English-language
publications, contacting study authors to request additional
data to maximise the number of included studies, and an
outcome which required biochemically defined CKD ra-
ther than more heterogeneous and less precise clinical
diagnostic labels.
As with any systematic review, our findings are
dependent upon the size and quality of the published lit-
erature. There was only a small number of studies that
had examined either CKD or nephrolithiasis. Studies of
CKD were all published from 2007 onwards, which is
not surprising as the National Kidney Foundation CKD
classification was only introduced in 2002 [19]. Widen-
ing the outcome definition to include clinical diagnostic
labels for kidney disease would have increased the num-
ber of available studies but would have increased het-
erogeneity. Furthermore, CKD classification is widely
used and highly relevant to clinical practice. The small
number of published studies also raises the possibility of
publication bias. Although not evident for nephrolithiasis,
there were too few studies of CKD to examine for publica-
tion bias. There were several methodological limitations
of the included studies worthy of further discussion. Themajority of included studies were not designed with the
primary aim of assessing the association between gout and
CKD/nephrolithiasis. Most studies based the diagnosis of
gout on physician diagnosis (which has been shown to be
reasonably accurate [49]) or patient self-report rather than
more rigorous methods such as the American Rheuma-
tism Association criteria [50] or crystal identification. This
limitation risks misclassification bias but, as highlighted
by this study, the current evidence base offers limited
numbers of epidemiological studies using more robust
methods. Several studies did not include control groups
without gout and only reported the prevalence of CKD/
nephrolithiasis in gout but not the strength of association
between the two. Although our findings demonstrate a
clear independent association between gout and both
CKD and nephrolithiasis, there were few prospective
studies so we could not draw firm conclusions about
temporal aspects of these associations. Previous epi-
demiological studies have shown that chronic renal dis-
ease is an independent risk factor for gout [10,11], yet
there are several plausible mechanisms by which gout
might predispose to CKD. Renal damage can result from
co-morbid hypertension and diabetes, hyperuricaemia-
mediated endothelial dysfunction and renovascular dis-
ease [55], and use of nonsteroidal anti-inflammatory
drugs. Although allopurinol is widely believed to have a
deleterious effect on renal function based on early observa-
tions [56], a recent systematic review suggested that it may
protect against progression of CKD [57]. Inflammation in
gout is increasingly recognised to persist in the inter-
critical period between acute attacks [58,59], raising the
possibility that inflammatory mechanisms contribute to
vascular risk, as has been proposed for other inflammatory
arthropathies [60]. Statistical heterogeneity was demon-
strated in the meta-analyses for CKD and nephrolithiasis
prevalence, the unadjusted HR between gout and incident
ESRD, and the unadjusted and age-adjusted and gender-
adjusted ORs between gout and nephrolithiasis. Possible
sources include differences between the demographic and
co-morbid characteristics of the populations studied and
the different follow-up periods in the prospective studies.
It is noteworthy, however, that the pooled multivariate es-
timates adjusting for such demographic and co-morbid
factors did not demonstrate significant heterogeneity.
Conclusions
The main clinical implications of our findings are that
patients with gout should be screened for CKD and that
clinicians should be made aware of the associations be-
tween gout and CKD/nephrolithiasis. Unless sought for,
CKD usually progresses subclinically until reaching more
advanced stages. In view of this, the significant morbid-
ity and mortality associated with CKD [8] and the risk of
CKD associated with gout, a presentation with gout in
Roughley et al. Arthritis Research & Therapy  (2015) 17:90 Page 11 of 12primary care should be viewed as a red flag for CKD and
should prompt screening for and treatment of both
CKD and its associated risk factors such as hypertension
and diabetes mellitus, which are also risk factors for gout
[10]. American College of Rheumatology guidelines ad-
vise considering CKD and nephrolithiasis as part of the
management of gout [61] but current national and inter-
national guidelines regarding CKD [62] and nephrolithia-
sis [63] do not recognise gout as a risk factor for these
conditions. Only one in five people presenting to primary
care with acute gout are screened for CKD within a month
of presentation [64].
In summary, gout is associated with both CKD and
nephrolithiasis. However, there were insufficient prospect-
ive studies to determine the temporal nature of these asso-
ciations or to determine the mechanisms underlying them.
Whilst the associations seen suggest that clinicians should
be made aware of them and that patients with gout should
be screened for CKD, further studies are required to inves-
tigate these relationships further.
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